Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

CAIRE Inc., a subsidiary of NGK SPARK PLUG CO., LTD., will acquire St. Paul, Minnesota-based MGC Diagnostics Holdings, Inc. (MGC).

On November 28th China Biologics public release said that the company's anti-neoconazole monoclonal antibody F61 nasal spray developed by the company was approved for clinical use.

Liquid biopsy firm SeekIn said Monday that it has received a CE mark for its cancer recurrence monitoring test, SeekInCure, and is preparing to launch assay kits in the European Union and other countries that recognize the designation.

Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.

According to the WeChat public account of Peking Union Medical College Hospital on November 21, the peripheral blood cell image leukocyte assisted recognition software jointly developed by the Laboratory Department of Peking Union Medical College Hospital and Beijing Xiaofly Technology passed

Cue Health on Wednesday afternoon announced that revenues for the third quarter beat both Wall Street expectations and previous guidance from the firm.

DNAscope, a germline variant-calling pipeline from San Jose-based analytics firm Sentieon, achieved superior SNP and indel accuracy as compared to other standard datasets, according to a recent preprint from the company.

The 86th China International Medical Equipment Fair (CMEF) was suspended in consideration of the health and safety of all participants.

A slower-than-expected recovery in certain procedures, including TAVR and spinal cord stimulation, curbed quarterly profit and revenue.

Avacta, a UK-based developer of cancer immunotherapies and diagnostics, said on Tuesday that it has signed an agreement to acquire Launch Diagnostics for up to ￡37 million ($41.9 million).